Zydus receives final approval from USFDA for Tretinoin Cream USP, 0.1%

Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as "Zydus") has received final approval from the United States Food and Drug Administration (USFDA) to market Tretinoin Cream USP, 0.1%, (USRLD: Retin-A Cream, 0.1%).

Tretinoin cream is used to treat acne. The drug will be manufactured at the group's topical manufacturing facility at Changodar, Ahmedabad (India).

Tretinoin Cream USP, 0.1% had annual sales of USD 54.8 mn in the United States (IQVIA MAT Feb-24).

The group now has 394 approvals and has so far filed over 460* ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Cadila Healthcare Limited was last trading in BSE at Rs. 947.90 as compared to the previous close of Rs. 950.95. The total number of shares traded during the day was 24168 in over 1207 trades.

The stock hit an intraday high of Rs. 958.00 and intraday low of 945.00. The net turnover during the day was Rs. 22964237.00.

(*as of 31st December 2023)

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 Pharmaceuticals USFDA FinalApproval TretinoinCream